Processa Pharmaceuticals (PCSA) Change in Accured Expenses (2012 - 2026)
Processa Pharmaceuticals' (PCSA) quarterly Change in Accured Expenses came in at -$39734.0 in Q1 2026, down 138.95% YoY from $102016.0 in Q1 2025, and down 125.53% on a QoQ basis from $155651.0 in Q4 2025.
Processa Pharmaceuticals (PCSA) Change in Accured Expenses (2012 - 2026) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 15 years of Change in Accured Expenses data on file, last reported at -$39734.0 in Q1 2026.
- Quarterly Change in Accured Expenses fell 138.95% year-over-year to -$39734.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $458976.0 (up 113.35% YoY) and the FY2025 annual result came in at $600726.0, up 38.91% from the prior year.
- Change in Accured Expenses eased to -$39734.0 in Q1 2026, from $155651.0 in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $582496.0 in Q2 2025 to a low of -$239437.0 in Q3 2025.
- A 5-year average of $57674.0 and a median of $14846.0 in 2022 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2023 — Change in Accured Expenses plunged 1152.36% — and 2025, when it jumped 1364.33%.
- Tracing PCSA's Change in Accured Expenses over 5 years: stood at $306654.0 in 2022, then slumped by 118.25% to -$55962.0 in 2023, then jumped by 396.48% to $165918.0 in 2024, then slipped by 6.19% to $155651.0 in 2025, then slumped by 125.53% to -$39734.0 in 2026.
- The last three Change in Accured Expenses figures came in at -$39734.0 (Q1 2026), $155651.0 (Q4 2025), and -$239437.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Processa Pharmaceuticals | 5.69 Mn | 5.69 Mn | - | -412,258.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -39,734.00 |
| Mar 31, 2026 | -39,734.00 |
| Dec 31, 2025 | 155,651.00 |
| Dec 31, 2025 | 155,651.00 |
| Sep 30, 2025 | -239,437.00 |
| Sep 30, 2025 | -239,437.00 |
| Jun 30, 2025 | 582,496.00 |
| Jun 30, 2025 | 582,496.00 |
| Mar 31, 2025 | 102,016.00 |
| Mar 31, 2025 | 102,016.00 |
| Dec 31, 2024 | 165,918.00 |
| Dec 31, 2024 | 165,918.00 |
| Sep 30, 2024 | -92,584.00 |
| Sep 30, 2024 | -92,584.00 |
| Jun 30, 2024 | 39,779.00 |
| Jun 30, 2024 | 39,779.00 |
| Mar 31, 2024 | 319,344.00 |
| Mar 31, 2024 | 319,344.00 |
| Dec 31, 2023 | -55,962.00 |
| Dec 31, 2023 | -55,962.00 |